Search

Your search keyword '"Seneschal, J"' showing total 34 results
Start Over Author "Seneschal, J" Publisher wiley
34 results on '"Seneschal, J"'

7. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

Author

Ring, J., primary, Worm, M., additional, Wollenberg, A., additional, Thyssen, J.P., additional, Jakob, T., additional, Klimek, L., additional, Bangert, C., additional, Barbarot, S., additional, Bieber, T., additional, Bruin‐Weller, M.S., additional, Chernyshov, P.V., additional, Christen‐Zaech, S., additional, Cork, M., additional, Darsow, U., additional, Flohr, C., additional, Fölster‐Holst, R., additional, Gelmetti, C., additional, Gieler, U., additional, Gutermuth, J., additional, Heratizadeh, A., additional, Hijnen, D.J., additional, Kobyletzki, L.B., additional, Kunz, B., additional, Paul, C., additional, De Raeve, L., additional, Seneschal, J., additional, Simon, D., additional, Spuls, P.I., additional, Stalder, J.F., additional, Svensson, A., additional, Szalai, Z., additional, Taieb, A., additional, Torrelo, A., additional, Trzeciak, M., additional, Vestergaard, C., additional, Werfel, T., additional, Weidinger, S., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

8. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Barbarot, S., additional, de Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, von Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Christen‐Zaech, S., additional, Hijnen, D.J., additional, Gieler, U., additional, Gutermuth, J., additional, Bangert, C., additional, Spuls, P.I., additional, Kunz, B., additional, Ring, J., additional, Wollenberg, A., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

9. European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

Author

Wollenberg, A., Flohr, C., Simon, D., Cork, M.J., Thyssen, J.P., Bieber, T., de Bruin-Weller, M.S., Weidinger, S., Deleuran, M., Taieb, A., Paul, C., Trzeciak, M., Werfel, T., Seneschal, J., Barbarot, S., Darsow, U., Torrelo, A., Stalder, J.-F., Svensson, Å., Hijnen, D., Gelmetti, C., Szalai, Z., Gieler, U., De Raeve, L., Kunz, B., Spuls, P., von Kobyletzki, L.B., Fölster-Holst, R., Chernyshov, P.V., Cristen-Zaech, S., Heratizadeh, A., Ring, J., and Vestergaard, C.

Abstract

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities. Severely affected patients are often treated with immune‐modulating systemic drugs. On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS‐Cov‐2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno‐compromised, or have comorbidities. This also applies to AD patients on systemic immune‐modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune‐modulating treatment of AD patients. The ETFAD decided to address some of these questions here.

Published
2020

10. Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study

Author

Richard, M.‐A., primary, Paul, C., additional, De Pouvourville, G., additional, Jullien, D., additional, Mahe, E., additional, Bachelez, H., additional, Seneschal, J., additional, Misery, L., additional, Aubert, R., additional, Reguiai, Z., additional, Shourick, J., additional, Taieb, C., additional, Joly, P., additional, and Ezzedine, K., additional

Published
2020
Full Text
View/download PDF

11. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Deleuran, M., additional, Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Barbarot, S., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Cristen‐Zaech, S., additional, Hijnen, D., additional, Gieler, U., additional, Ring, J., additional, and Wollenberg, A., additional

Published
2020
Full Text
View/download PDF

12. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)

Author

Seneschal, J., primary, Lacour, J.‐P., additional, Bewley, A., additional, Faurby, M., additional, Paul, C., additional, Pellacani, G., additional, De Simone, C., additional, Horne, L., additional, Sohrt, A., additional, Augustin, M., additional, Hammond, E., additional, and Reich, K., additional

Published
2020
Full Text
View/download PDF

13. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

Author

Wollenberg, A., primary, Flohr, C., additional, Simon, D., additional, Cork, M.J., additional, Thyssen, J.P., additional, Bieber, T., additional, Bruin‐Weller, M.S., additional, Weidinger, S., additional, Deleuran, M., additional, Taieb, A., additional, Paul, C., additional, Trzeciak, M., additional, Werfel, T., additional, Seneschal, J., additional, Barbarot, S., additional, Darsow, U., additional, Torrelo, A., additional, Stalder, J.‐F., additional, Svensson, Å., additional, Hijnen, D., additional, Gelmetti, C., additional, Szalai, Z., additional, Gieler, U., additional, De Raeve, L., additional, Kunz, B., additional, Spuls, P., additional, Kobyletzki, L.B., additional, Fölster‐Holst, R., additional, Chernyshov, P.V., additional, Christen‐Zaech, S., additional, Heratizadeh, A., additional, Ring, J., additional, and Vestergaard, C., additional

Published
2020
Full Text
View/download PDF

16. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Author

Vestergaard, C., primary, Wollenberg, A., additional, Barbarot, S., additional, Christen‐Zaech, S., additional, Deleuran, M., additional, Spuls, P., additional, Flohr, C., additional, Trzeciak, M., additional, von Kobyletzki, L., additional, Seneschal, J., additional, Paul, C., additional, Bieber, T., additional, Werfel, T., additional, Fölster‐Holst, R., additional, Darsow, U., additional, Gieler, U., additional, Svensson, Å., additional, Cork, M., additional, Stalder, J.‐F., additional, De Raeve, L., additional, Kunz, B., additional, Simon, D., additional, Chernyshov, P., additional, Hijnen, D., additional, Gelmetti, C., additional, Ring, J., additional, Taieb, A., additional, de Bruin‐Weller, M., additional, and Thyssen, J.P., additional

Published
2019
Full Text
View/download PDF

20. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., Krieg, T., Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., and Krieg, T.

Abstract

The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first-and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.

Published
2017

21. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author

Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., Krieg, T., Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., and Krieg, T.

Abstract

The term sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).

Published
2017

22. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Knobler, Robert, Moinzadeh, Pia, Hunzelmann, Nicolas, Kreuter, Alexander, Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, Franco, Denton, C.P., Rudnicka, Lidia, Frasin, L.A., Smith, V., Gabrielli, A., Aberer, Elisabeth, Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, Ivan, Frances, C., Jalili, A., Just, U., Kähäri, V., Karpati, Sarolta, Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, Margitta, Wutte, N.J., Krieg, Thomas M., Knobler, Robert, Moinzadeh, Pia, Hunzelmann, Nicolas, Kreuter, Alexander, Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, Franco, Denton, C.P., Rudnicka, Lidia, Frasin, L.A., Smith, V., Gabrielli, A., Aberer, Elisabeth, Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, Ivan, Frances, C., Jalili, A., Just, U., Kähäri, V., Karpati, Sarolta, Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, Margitta, Wutte, N.J., and Krieg, Thomas M.

Published
2017

23. European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author

Knobler, Robert, Moinzadeh, Pia, Hunzelmann, Nicolas, Kreuter, Alexander, Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, Franco, Denton, C.P., Rudnicka, Lidia, Frasin, L.A., Smith, V., Gabrielli, A., Aberer, Elisabeth, Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, Ivan, Frances, C., Jalili, A., Just, U., Kähäri, Veli-Matti, Karpati, Sarolta, Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, Margitta, Wutte, N.J., Krieg, Thomas M., Knobler, Robert, Moinzadeh, Pia, Hunzelmann, Nicolas, Kreuter, Alexander, Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, Franco, Denton, C.P., Rudnicka, Lidia, Frasin, L.A., Smith, V., Gabrielli, A., Aberer, Elisabeth, Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, Ivan, Frances, C., Jalili, A., Just, U., Kähäri, Veli-Matti, Karpati, Sarolta, Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, Margitta, Wutte, N.J., and Krieg, Thomas M.

Published
2017

24. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author

Knobler, R., primary, Moinzadeh, P., additional, Hunzelmann, N., additional, Kreuter, A., additional, Cozzio, A., additional, Mouthon, L., additional, Cutolo, M., additional, Rongioletti, F., additional, Denton, C.P., additional, Rudnicka, L., additional, Frasin, L.A., additional, Smith, V., additional, Gabrielli, A., additional, Aberer, E., additional, Bagot, M., additional, Bali, G., additional, Bouaziz, J., additional, Braae Olesen, A., additional, Foeldvari, I., additional, Frances, C., additional, Jalili, A., additional, Just, U., additional, Kähäri, V., additional, Kárpáti, S., additional, Kofoed, K., additional, Krasowska, D., additional, Olszewska, M., additional, Orteu, C., additional, Panelius, J., additional, Parodi, A., additional, Petit, A., additional, Quaglino, P., additional, Ranki, A., additional, Sanchez Schmidt, J.M., additional, Seneschal, J., additional, Skrok, A., additional, Sticherling, M., additional, Sunderkötter, C., additional, Taieb, A., additional, Tanew, A., additional, Wolf, P., additional, Worm, M., additional, Wutte, N.J., additional, and Krieg, T., additional

Published
2017
Full Text
View/download PDF

25. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author

Knobler, R., primary, Moinzadeh, P., additional, Hunzelmann, N., additional, Kreuter, A., additional, Cozzio, A., additional, Mouthon, L., additional, Cutolo, M., additional, Rongioletti, F., additional, Denton, C.P., additional, Rudnicka, L., additional, Frasin, L.A., additional, Smith, V., additional, Gabrielli, A., additional, Aberer, E., additional, Bagot, M., additional, Bali, G., additional, Bouaziz, J., additional, Braae Olesen, A., additional, Foeldvari, I., additional, Frances, C., additional, Jalili, A., additional, Just, U., additional, Kähäri, V., additional, Kárpáti, S., additional, Kofoed, K., additional, Krasowska, D., additional, Olszewska, M., additional, Orteu, C., additional, Panelius, J., additional, Parodi, A., additional, Petit, A., additional, Quaglino, P., additional, Ranki, A., additional, Sanchez Schmidt, J.M., additional, Seneschal, J., additional, Skrok, A., additional, Sticherling, M., additional, Sunderkötter, C., additional, Taieb, A., additional, Tanew, A., additional, Wolf, P., additional, Worm, M., additional, Wutte, N.J., additional, and Krieg, T., additional

Published
2017
Full Text
View/download PDF

26. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score

Author

Stalder, J.‐F., primary, Aubert, H., additional, Anthoine, E., additional, Futamura, M., additional, Marcoux, D., additional, Morren, M.‐A., additional, Trzeciak, M., additional, Szalai, Z., additional, Veres, K., additional, Deleuran, M., additional, Vestergaard, C., additional, Boralevi, F., additional, Chu, C.‐Y., additional, De Raeve, L., additional, Svensson, Å., additional, Fölster‐Holst, R., additional, Buchner, M., additional, Takaoka, R., additional, Aoki, V., additional, Chernyshov, P., additional, Chernyshova, L., additional, Murrell, D. F., additional, Zhao, C., additional, Mckinster, C. D., additional, Von Kobyletzky, L., additional, Eichenfield, L., additional, Totri, C., additional, Lio, P., additional, Seneschal, J., additional, Moret, L., additional, and Barbarot, S., additional

Published
2017
Full Text
View/download PDF

31. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis

Author

Thyssen, J P, Vestergaard, C, Deleuran, M, de Bruin-Weller, M S, Bieber, T, Taieb, A, Seneschal, J, Cork, M J, Paul, C, Flohr, C, Weidinger, S, Trzeciak, M, Werfel, T, Heratizadeh, A, Barbarot, S, Darsow, U, Simon, D, Torrelo, A, Chernyshov, P V, Stalder, J-F, Gelmetti, C, Szalai, Z, Svensson, Å, von Kobyletzki, L B, De Raeve, L, Fölster-Holst, R, Cristen-Zaech, S, Hijnen, D, Gieler, U, Ring, J, and Wollenberg, A

Subjects
610 Medicine & health, 3. Good health

32. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis

Author

Wollenberg, A, Flohr, C, Simon, Dagmar, Cork, M J, Thyssen, J P, Bieber, T, de Bruin-Weller, M S, Weidinger, S, Deleuran, M, Taieb, A, Paul, C, Trzeciak, M, Werfel, T, Seneschal, J, Barbarot, S, Darsow, U, Torrelo, A, Stalder, J-F, Svensson, Å, Hijnen, D, Gelmetti, C, Szalai, Z, Gieler, U, De Raeve, L, Kunz, B, Spuls, P, von Kobyletzki, L B, Fölster-Holst, R, Chernyshov, P V, Christen-Zaech, S, Heratizadeh, A, Ring, J, and Vestergaard, C

Subjects
610 Medicine & health, 3. Good health

33. Interleukin-1β-Activated Microvascular Endothelial Cells Promote DC-SIGN-Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis.

Author

Laurent P, Lapoirie J, Leleu D, Levionnois E, Grenier C, Jurado-Mestre B, Lazaro E, Duffau P, Richez C, Seneschal J, Pellegrin JL, Constans J, Schaeverbeke T, Douchet I, Duluc D, Pradeu T, Chizzolini C, Blanco P, Truchetet ME, and Contin-Bordes C

Subjects
Fibrosis, Humans, Macrophage Activation, Macrophages, Skin pathology, Cell Adhesion Molecules immunology, Endothelial Cells metabolism, Interleukin-1beta immunology, Lectins, C-Type immunology, Receptors, Cell Surface immunology, Scleroderma, Systemic pathology
Abstract

Objective: To characterize the role of interleukin-1β (IL-1β) and microvascular endothelial cells (MVECs) in the generation of alternatively activated macrophages in the skin, and to explore their role in the development of skin fibrosis in patients with systemic sclerosis (SSc; scleroderma)., Methods: Conditioned medium prepared with MVECs purified from the skin of healthy donors and the skin of SSc patients was used to generate monocyte-derived macrophages. Flow cytometry, multiplex protein assessment, real-time quantitative polymerase chain reaction, and tissue immunofluorescence were used to characterize MVEC-induced polarization of alternatively activated macrophages. Coculture experiments were conducted to assess the role of MVEC-induced alternatively activated macrophages in fibroblast activation. Alternatively activated macrophages were characterized in the skin of healthy donors and SSc patients using multiparametric immunofluorescence and multiplex immunostaining for gene expression. Based on our in vitro data, we defined a supervised macrophage gene signature score to assess correlation between the macrophage score and clinical features in patients with SSc, using the Spearman's test., Results: IL-1β-activated MVECs from SSc patients induced monocytes to differentiate into DC-SIGN+ alternatively activated macrophages producing high levels of CCL18, CCL2, and CXCL8 but low levels of IL-10. DC-SIGN+ alternatively activated macrophages showed significant enhancing effects in promoting the production of proinflammatory fibroblasts and were found to be enriched in perivascular regions of the skin of SSc patients who had a high fibrosis severity score. A novel skin transcriptomic macrophage signature, defined from our in vitro findings, correlated with the extent of skin fibrosis (Spearman's r = 0.6, P = 0.0018) and was associated with early disease manifestations and lung involvement in patients with SSc., Conclusion: Our findings shed new light on the vicious circle implicating unabated IL-1β secretion, MVEC activation, and the generation of DC-SIGN+ alternatively activated macrophages in the development of skin fibrosis in patients with SSc., (© 2021 American College of Rheumatology.)

Published
2022
Full Text
View/download PDF

34. Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis.

Author

Truchetet ME, Demoures B, Eduardo Guimaraes J, Bertrand A, Laurent P, Jolivel V, Douchet I, Jacquemin C, Khoryati L, Duffau P, Lazaro E, Richez C, Seneschal J, Doutre MS, Pellegrin JL, Constans J, Schaeverbeke T, Blanco P, and Contin-Bordes C

Subjects
Adult, Blood Platelets, Case-Control Studies, Cells, Cultured, Dermis blood supply, Enzyme-Linked Immunosorbent Assay, Female, Fibrosis, Fluorescent Antibody Technique, Humans, Immunohistochemistry, In Vitro Techniques, Interleukin-1beta metabolism, Male, Microvessels cytology, Middle Aged, Real-Time Polymerase Chain Reaction, Scleroderma, Diffuse metabolism, Scleroderma, Diffuse pathology, Scleroderma, Limited metabolism, Scleroderma, Limited pathology, Scleroderma, Systemic pathology, Skin cytology, Thymic Stromal Lymphopoietin, Cytokines metabolism, Endothelial Cells metabolism, Extracellular Matrix genetics, Fibroblasts metabolism, Scleroderma, Systemic metabolism, Skin pathology
Abstract

Objective: To investigate the relationship between vascular damage and fibrosis in systemic sclerosis (SSc) by testing the hypothesis that platelets contribute to skin fibrosis via the activation of human dermal microvascular endothelial cells (HDMECs) and subsequent production of profibrotic mediators., Methods: A total of 203 SSc patients and 30 healthy donors were prospectively enrolled between 2012 and 2015 at the University Hospital of Bordeaux. Immunohistochemistry and immunofluorescence analyses were performed on skin biopsy sections from 18 SSc patients and 5 healthy donors. Serum thymic stromal lymphopoietin (TSLP) levels were measured by enzyme-linked immunosorbent assay in the entire cohort. HDMECs and fibroblasts were purified from biopsy sections. Extracellular matrix production by cultured fibroblasts was assessed by real-time quantitative polymerase chain reaction., Results: Serum TSLP levels were significantly increased in SSc patients compared to healthy donors (P < 0.0001) and were associated with a higher frequency of vasculopathy (P = 0.02). The proportion of TSLP-positive dermal cells was increased in the skin of SSc patients compared with healthy donors (P < 0.0001) and was correlated with fibrosis (modified Rodnan skin thickness score) (r = 0.6146, P = 0.0001). In SSc dermis, TSLP was mainly expressed by CD31-positive endothelial cells. In vitro, activated platelets induced TSLP production by HDMECs in an interleukin-1β-dependent manner. SSc fibroblasts responded differently according to their original TSLP environment., Conclusion: Taken together, these results identify HDMECs as contributors to TSLP production in SSc and suggest a potential mechanism by which platelets may profoundly affect the fibrotic process in SSc., (© 2016, American College of Rheumatology.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results